Passionate impact investor in healthcare willing to take bets where few would dare. A statistician by education, Michele has managed over a $ bn in both public and private investments. Michele sits on the board of several companies, mostly on the healthcare space.
Location
Italy
Notable investments
No items found.
Check size range(s)
$500K - $1M
Rounds their fund invests in
Pre-Seed
Seed
Series A
Series B+
Rounds their fund leads
No items found.
Sectors their fund invests in
Biotech
Deeptech
Health
Geographies their fund invests in
USA
Canada
Europe
Israel
Browse through a massive startup database
Browse Harmonic, our favorite resource for parsing through the world's startup data.
Partner
Learn more about Harmonic
No items found.
No colleagues here yet.
Funds they're a part of
Health Technology Holding (HTH)
About the Fund
HTH is a full fledge investment and advisory company investing alongside bright innovators dedicated to improve humans’ health.
Since 2016, the team has been working closely with pharma companies to successfully invest in life science ventures and to provide innovation capabilities to large corporations.
As an Investor, HTH is an hands-on actor, taking pro-active roles in early stages startup providing not just capital, but opening companies to a vast network of possible stakeholders. As an advisor, HTH provides client with the best solutions to approach life science and strives to open innovation pathways and opportunities for its clients.
They have a scientific-based approach: for them there is no business if there is no science. For HTH, PoC data, scientific rationale, animal models, MoA understanding are pillars of the due diligence process. Usually, they undergo a deep analysis phase, in which we also undertake interview to clinicians, KOLs, patient associations etc. Their due diligence process last no more than 1 or 2 months.
Since 2016, the team has been working closely with pharma companies to successfully invest in life science ventures and to provide innovation capabilities to large corporations.
As an Investor, HTH is an hands-on actor, taking pro-active roles in early stages startup providing not just capital, but opening companies to a vast network of possible stakeholders. As an advisor, HTH provides client with the best solutions to approach life science and strives to open innovation pathways and opportunities for its clients.
They have a scientific-based approach: for them there is no business if there is no science. For HTH, PoC data, scientific rationale, animal models, MoA understanding are pillars of the due diligence process. Usually, they undergo a deep analysis phase, in which we also undertake interview to clinicians, KOLs, patient associations etc. Their due diligence process last no more than 1 or 2 months.
View Profile
Their Colleagues
Sheets Their fund(s) are in
Is this you? Have any edits?
Fill out our update request form and we'll update ASAP
Related Investors
Round-focused Sheets
Geography-focused Sheets
Sector-focused Sheets
